PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1380851

Recurrent chromosome alterations in transitional cell bladder carcinomas.

L Matturri·A M Lavezzi
View original source ↗Export metadata ↓

Abstract

A karyotype study was performed in 42 cases of transitional cell bladder carcinoma. The results, confirmed by DNA content evaluation, showed a prevalence of near-diploid modes not related to the histologic grade of differentiation. Nonrandom alterations were represented by monosomy of chromosome 13 and 22, trisomy of chromosome 7 and deletion of chromosomes 6 and 11. These anomalies allow the identification of different sub-groups of tumors, each with its own biological characteristics of aggressiveness. Prognosis was particularly poor in cases with monosomy of chromosomes 13 and 22 but more favourable in poorly differentiated carcinomas with trisomy of chromosome 7.

Explore related subjects

Carcinoma, Transitional CellChromosome AberrationsHumansKaryotypingStaining and LabelingUrinary Bladder NeoplasmsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Matturri, A M Lavezzi. 1992. Recurrent chromosome alterations in transitional cell bladder carcinomas.. https://pubmed.ncbi.nlm.nih.gov/1380851/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Trimodality treatment and selective organ preservation for bladder cancer.

Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment, including transurethral resection of the bladder tumor (TURBT), radiation therapy and chemotherapy, has been shown to produce survival rates comparable to those of cystectomy. With these programs, cystectomy has been reserved for patients with incomplete response or local relapse. During the past 15 years, organ preservation by trimodality treatment has been investigated in prospective series from single centers and cooperative groups, with more than 1,000 patients included. Five-year overall survival rates in the range of 50% to 60% have been reported, and approximately three quarters of the surviving patients maintained their bladder. Clinical criteria helpful in determining ideal patients for bladder preservation include early tumor stage (including high-risk T1 disease), a visibly complete TURBT, and absence of ureteral obstruction. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on (1) optimizing radiation techniques and incorporating more effective systemic chemotherapy, and (2) the proper selection of patients based on molecular makers.

Carcinoma, Transitional Cell↗